Literature DB >> 24730359

Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation.

J M Pascasio1, I Grilo, F J López-Pardo, F Ortega-Ruiz, J L Tirado, J M Sousa, M J Rodriguez-Puras, M T Ferrer, M Sayago, M A Gómez-Bravo, A Grilo.   

Abstract

The prevalence of hepatopulmonary syndrome (HPS) and its influence on survival before and after liver transplantation (LT) remain controversial. Additionally, the chronology of post-LT reversibility is unclear. This study prospectively analyzed 316 patients with cirrhosis who were evaluated for LT in 2002-2007; 177 underwent LT at a single reference hospital. HPS was defined by a partial pressure of arterial oxygen (PaO2 ) <70 mmHg and/or an alveolar-arterial oxygen gradient (A-a PO2 ) ≥20 mmHg in the supine position and positive contrast echocardiography. The prevalence of HPS was 25.6% (81/316 patients), and most patients (92.6%) had mild or moderate HPS. High Child-Pugh scores and the presence of ascites were independently associated with HPS. Patients with and without HPS did not significantly differ in LT waiting list survival (mean 34.6 months vs. 41.6 months, respectively; log-rank, p = 0.13) or post-LT survival (mean 45 months vs. 47.6 months, respectively; log-rank, p = 0.62). HPS was reversed in all cases within 1 year after LT. One-fourth of the patients with cirrhosis who were evaluated for LT had HPS (mostly mild to moderate); the presence of HPS did not affect LT waiting list survival. HPS was always reversed after LT, and patient prognosis did not worsen. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Ascites; echocardiography; portal hypertension; pulmonary vascular diseases and perioperative care

Mesh:

Year:  2014        PMID: 24730359     DOI: 10.1111/ajt.12713

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  14 in total

Review 1.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 2.  The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-28       Impact factor: 11.382

Review 3.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

4.  Assessing the kinetics of microbubble appearance in cirrhotic patients using transthoracic saline contrast-enhanced echocardiography.

Authors:  Adriano R Tonelli; Tawfeq Naal; Wael Dakkak; Margaret M Park; Raed A Dweik; James K Stoller
Journal:  Echocardiography       Date:  2017-08-25       Impact factor: 1.724

Review 5.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

6.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

7.  Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis.

Authors:  Arun Jose; Shimul A Shah; Nadeem Anwar; Courtney R Jones; Francis X McCormack; Kenneth E Sherman; Jean M Elwing
Journal:  Respir Med       Date:  2021-11-11       Impact factor: 3.415

8.  Dexmedetomidine Attenuates Bilirubin-Induced Lung Alveolar Epithelial Cell Death In Vitro and In Vivo.

Authors:  Jian Cui; Hailin Zhao; Bin Yi; Jing Zeng; Kaizhi Lu; Daqing Ma
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

9.  Inhibition of autophagy ameliorates pulmonary microvascular dilation and PMVECs excessive proliferation in rat experimental hepatopulmonary syndrome.

Authors:  Duo Xu; Bing Chen; Jianteng Gu; Lin Chen; Karine Belguise; Xiaobo Wang; Bin Yi; Kaizhi Lu
Journal:  Sci Rep       Date:  2016-08-02       Impact factor: 4.379

Review 10.  Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature.

Authors:  Caglar Cosarderelioglu; Arif M Cosar; Merve Gurakar; Nabil N Dagher; Ahmet Gurakar
Journal:  J Clin Transl Hepatol       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.